EHA 2025 | The ongoing Phase III QUINTESSENTIAL-2 trial of arlo-cel in adult patients with RRMM

Currently we have two BCMA targeted CAR T-cells available, namely cilta-cel and ide-cel. And whilst both of these agents are highly effective, there is a need for novel targeted approaches for CAR T-cell therapy, particularly because we’re already using bispecific antibodies targeting BCMA. So the QUINTESSENTIAL-2 clinical trial is the Phase III clinical trial investigating arlo-cel. Arlo-cel is a GPRC5D targeting CAR T-cell therapy which has already been investigated in Phase I clinical trials and has demonstrated a very high response rate over 80% and durable responses. So clearly we’re already seeing an early signal in terms of efficacy of this compound and the next question therefore is to see whether it’s superior to standard of care treatments. So the QUINTESSENTIAL-2 study is a Phase III randomized clinical trial for patients who’ve had between one and three prior lines of therapy who are refractory to lenalidomide because most patients at first line are now emerging to be lenalidomide refractory. And they’re randomized in a one-to-one level to either receive arlo-cel which is followed by lymphodepletion chemotherapy or standard of care. The standard of care approaches are daratumumab, pomalidomide, dexamethasone or carfilzomib and dexamethasone. And just to reiterate that the CAR T-cell therapy is a one-off treatment, whereas the ongoing standard of care treatment is treat until progression. This study is a global study and is currently enrolling, and we’re looking forward to continuing that and reporting results in the future.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.